[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498837":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":37,"locations":47,"responsibleParty":62,"collaborators":64,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":10,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"National Heart Centre Singapore","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1 (significant CAD, low risk factors)",null,"1. Evidence of significant CAD\n\n   a. Coronary angiogram or CT coronary angiogram with documented stenosis \\>=50% in left main or \\>=70% in major epicardial vessel or major branches (LAD, LCX, RCA)\n\n   AND all of the following\n2. Age \\\u003C\u002F= 45 for males and \\\u003C\u002F= 50 for females\n3. Absence of diabetes mellitus\n4. Absence of tobacco use\n5. No prior CVA or PAD",[13],"Procedure: Blood draw",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2 (minor CAD, high risk factors)","1. No evidence of significant CAD\n\n   a. Coronary angiogram or CT coronary angiogram with \\\u003C50% stenosis in major blood vessel\u002Fbranch\n2. No prior history of clinical CAD, PAD or CVA\n\n   with one of the\n3. Age \\>65 with\n\n   1. Diabetes mellitus \\>5years; or\n   2. End Stage Renal Failure (ESRF), regardless of duration or\n   3. Framingham risk score \\> 10%\n4. Diabetes \\>10 years\n5. End Stage Renal Failure (ESRF) \\> 5 years\n6. Age \\>80",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Group 3 (signifcant CAD, high risk factors)","1\\. Evidence of significant CAD with one of the following:\n\n1. age\\>65\n2. Diabetes mellitus\n3. End Stage Renal Failure (ESRF)\n4. Framingham risk score \\>10%",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Group 4 Control group","1\\. No evidence of significant CAD and all of the following:\n\n1. Age \\\u003C55 for males, \\\u003C65 for females\n2. Absence of diabetes mellitus\n3. Absence of CKD\n4. Absence of tobacco use",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"PROCEDURE","Blood draw","2 6ml blood tubes will be collected from patient",[9,15,19,23],[33],{"name":34,"affiliation":35,"role":36},"Khyung Keong Yeo","National Heart Centre","PRINCIPAL_INVESTIGATOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":41,"email":42},"Aishah Toh","CONTACT","67042282","aishah.toh@nhcs.com.sg",{"name":44,"role":40,"phone":45,"phoneExt":45,"email":46},"Pei Yi Ho","67042234","ho.pei.yi@nhcs.com.sg",[48],{"facility":5,"status":49,"city":50,"state":10,"zip":51,"country":50,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Singapore","169609","SG",{"type":54,"coordinates":55},"Point",[56,57],103.85007,1.28967,{"lat":57,"lon":56},[60],{"name":39,"role":40,"phone":10,"phoneExt":61,"email":42},"2282",{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[65],{"name":66,"class":6},"Duke-NUS Graduate Medical School","100498837","extremes-of-coronary-artery-disease-and-normalitycad-extremes-100498837",false,"NCT05775445","Extremes of Coronary Artery Disease and Normality:CAD Extremes","Extremes of Coronary Artery Disease and Normality: Understanding Novel Causative and Protective Factors in the Development of Coronary Artery Disease (CAD Extremes)","Inclusion Criteria:\n\nGroup 1:\n\n1. Evidence of significant CAD a. Coronary angiogram or CT coronary angiogram with documented stenosis \\>=50% in left main or \\>=70% in major epicardial vessel or major branches (LAD, LCX, RCA)\n\n   AND all of the following\n2. Age \\\u003C\u002F= 45 for males and \\\u003C\u002F= 50 for females\n3. Absence of diabetes mellitus\n4. Absence of tobacco use\n5. No prior CVA or PAD\n\nGroup 2\n\n1. Evidence of significant CAD\n\n   1. Coronary angiogram or CT coronary angiogram with documented stenosis \\>=50% in left main or \\>=70% in major epicardial vessel or major branches (LAD, LCX, RCA)\n\n   AND all of the following\n2. Age \\\u003C\u002F= 45 for males and \\\u003C\u002F= 50 for females\n3. Absence of diabetes mellitus\n4. Absence of tobacco use\n5. No prior CVA or PAD\n\nGroup 3 1. Evidence of significant CAD with one of the following:\n\n1. age\\>65\n2. Diabetes mellitus\n3. End Stage Renal Failure (ESRF)\n4. Framingham risk score \\>10%\n\nGroup 4\n\n1\\. No evidence of significant CAD and all of the following\n\n1. Age \\\u003C55 for males, \\\u003C65 for females\n2. Absence of diabetes mellitus\n3. Absence of CKD\n4. Absence of tobacco use\n\nExclusion Criteria:\n\n1. Prior history of cancer (excludes pre-cancerous lesions)\n2. Expected life expectancy less than 1 year\n3. Known autoimmune disease\n4. Psychiatric illness\n5. Chronic lung disease requiring long term medications or oxygen\n6. Chronic infective disease, including tuberculosis, hepatitis B and C; and HIV\n7. Inability to comply with study protocol\n8. Any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes","ALL","21 Years","99 Years",{"count":78,"type":79},1500,"ESTIMATED","OBSERVATIONAL","In the field of cardiovascular medicine, there are two differing groups of patients that remain puzzling to clinicians: patients who are not expected to have coronary artery disease (CAD) yet are diagnosed with significant CAD; and those who are have multiple risk factors for CAD but do not have CAD. Bats exhibit unique phenotypes including long lifespans and likely reduced atherosclerosis. Prior work has identified multiple molecular mechanisms of suppressing the activation of inflammasomes, causally linked to atherosclerosis. The investigators hypothesize there are different molecular markers that confer protection or increased risk for CAD, some of which may be similar to bats. Thus, the aim of this study is to identify molecular markers that contribute to or are protective against acute coronary syndrome (ACS) through analyzing the genetics, peripheral blood and atherosclerotic samples from both extreme patient groups using single-cell RNA sequencing and multi-omics approach. In addition, novel anti-atherosclerotic mechanisms and factors from bat studies will be assessed in the human samples. Identification of novel targets that prevent or cause CAD has the potential to aid in the early identification of high-risk patients and development of new therapeutics to combat this growing epidemic. To conduct this study, patients who have undergone a coronary angiogram or a CT coronary angiogram that fall into the both extremes will be recruited and blood samples will be taken for the above analysis. These will be compared to a group of controls (low risk without disease and high risk with disease).",[83],"Coronary Artery Disease","2024-02-19",{"date":86,"type":87},"2024-02-21","ACTUAL",{"date":89,"type":87},"2023-05-30",{"date":91,"type":79},"2027-12",{"name":5,"class":6},1]